ORGANOGENESIS HOLDINGS INC. Increase (Decrease) in Leasing Receivables
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Increase (Decrease) in Leasing Receivables of $2.12 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLeasingReceivables · last filed 2023-05-10
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in leasing receivables for the quarter ending 2023-03-31 was $2.12M, a 21.19% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in leasing receivables for the quarter ending 2022-12-31 was $1.76M, a 11.18% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in leasing receivables for the quarter ending 2022-09-30 was $1.78M, a 26.55% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in leasing receivables for the quarter ending 2022-06-30 was $1.72M, a 10.04% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in leasing receivables for fiscal 2022 was $7.01M, a 13.81% increase from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. increase (decrease) in leasing receivables for fiscal 2021 was $6.16M.
| Period end | Increase (Decrease) in Leasing Receivables 3 month | Increase (Decrease) in Leasing Receivables 6 month | Increase (Decrease) in Leasing Receivables 9 month | Increase (Decrease) in Leasing Receivables 12 month |
|---|---|---|---|---|
| 2023-03-31 | $2.12M 10-Q · filed 2023-05-10 | $3.88M derived: sum of 2 quarters · filed 2023-05-10 | $5.66M derived: sum of 3 quarters · filed 2023-05-10 | $7.38M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.53M derived: sum of 2 quarters · filed 2023-03-01 | $5.25M derived: sum of 3 quarters · filed 2023-03-01 | $7.01M 10-K · filed 2023-03-01 |
| 2022-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $3.50M derived: sum of 2 quarters · filed 2022-11-09 | $5.25M 10-Q · filed 2022-11-09 | $7.23M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.47M 10-Q · filed 2022-08-09 | $5.45M derived: sum of 3 quarters · filed 2023-05-10 | $6.85M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $1.75M 10-Q · filed 2023-05-10 | $3.73M derived: sum of 2 quarters · filed 2023-05-10 | $5.13M derived: sum of 3 quarters · filed 2023-05-10 | $6.70M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.38M derived: sum of 2 quarters · filed 2023-03-01 | $4.95M derived: sum of 3 quarters · filed 2023-03-01 | $6.16M 10-K · filed 2023-03-01 |
| 2021-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.97M derived: sum of 2 quarters · filed 2022-11-09 | $4.18M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.77M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |